[1] Erndest W, Christen MG.Current status of platinum-based antitumor Drugs[J]. Chem Rev, 1999, 99:2451.
[2] Yoshinori K, Kenji I. Cis-platinum(Ⅱ) complex of trans-L-1,2-diaminocyclo-hexane[P]. USA. 4169846. 1979-08-02.
[3] Koji O, Yuko H, Chihiro N. Platinum compound and process of preparing same[P].USA. US5290961. 1994-03-01.
[4] Frantiske Z, Anna CP. Oxaliplatin with a low content of accompanying impurities and a method for preparetion thereof[P]. USA. 7351846B2. 2008-04-01.
[5] Kidani Y. Oxaliplatin[J]. Drugs of the Future, 1989, 14(6):529.
[6] 何 健,刘伟平,李永年,等. 抗癌药奥沙利铂的一种新合成工艺[P].中国专利. CN1837223A. 2006-09-27.
[7] 黄毅岚,张 丹. HPLC法测定奥沙利铂有关物质的含量[J]. 中国药房,2008,19(1):50.
[8] 傅 萍,兰婉玲,张 蕾. 关于注射用奥沙利铂有关物质检查方法的探讨[J].药物分析杂志,2009,29(1):1850.
[9] 马 艺,王 鑫. 草酸铂周围神经毒性机制研究进展[J].国外医学肿瘤学分册,2005,32(3):234.
[10] Lara MP, Mario RD, Elena R, et al. Oxaliplatin-related neurotoxicity:How and Why?[J]. Oncology Hematology, 2006,59:159.
[11] 刘 颖,赵 俊,张 爽,等. 高效液相色谱法测定注射用奥沙利铂中草酸的含量[J]. 药物分析杂志, 2007,27(10):1565.
[12] 刘祝东,栾春芳,普绍平. 奥沙利铂及其手性异构体的高效液相色谱分析[J]. 贵金属,2007,28(2),49.
[13] Chris HT, Martin AG, Graham L, et al. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function[J]. Clic Cancer Res, 2007, 13(16):4832.
[14] Nicholas H, Ross B, Stephen B, et al. Oxaliplatin formulations[P]. USA. US 6306902 B1. 2001-10-23.
[15] Houssam I, Rolland YM. Pharmacertically stable preparetion of oxaliplatinum[P]. USA. 5716988A.1998-02-10.
[16] Sara L, Alessandro M, Cristina C. Platinum Derivative Pharmacertical Formulations[P]. USA. US6476048. 2002-11-05.
[17] Andre A, Cisternino A, Roy AL, et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection[J]. Am J Health Syst Pharm, 2007, 64:1950.
[18] Audrey J, Sandrine R, Marie CD, et al. Stability of oxaliplatin solution[J]. The Annals of Pharmacotherapy, 2009, 43:390.
[19] Satish CU, Manoj K, Ajeet KS, et al. Stable oxaliplatin formulation[P]. USA. US2007/0054957A1. 2007-03-08.
[20] Schridde E, Merbach BD. Concentrated solution of oxaliplatinum[P]. Europe. EP1466599.2004-10-13.
[21] Sara L, Alessandro M, Crestina C. Pharmaceutical formulation of a platium derivative[P]. USA. US2003/0109515 A1. 2003-06-12.
[22] Darryl VW, Aikun L. Oxaliplatin Formulations[P]. USA. US2005/0090544 A1. 2005-03-08.
[23] Darryl VW, Aikun L. Oxaliplatin Formulations[P]. USA.US2007/0155833 A1. 2007-04-05.
[24] Ibrahim H, Bayssas M. Pharmaceutical stable oxaliplatium preparation for parenteral administration[P]. Europe. EP1207875B1. 2002-05-29.
[25] Michaela R, Katrin W. Plastic bottle for oxaliplatin solution[P]. USA. US2008/0208141 A1. 2008-8-28.